Navigation Links
The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
Date:11/17/2009

WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Cancer Pain finds that the market segment for breakthrough pain (acute flares of pain on a background of controlled chronic pain) will experience the most robust annual growth over the next 10 years, increasing by more than 15 percent per year between 2008 and 2018. This is largely due to the launch and ongoing market penetration of several premium-priced novel opioid reformulations that include Cephalon's Fentora/Effentora and ProStrakan/Kyowa Hakko Kirin's Abstral, which are both reformulations of fentanyl. However, owing to generic availability and physician familiarity, older opioids such as immediate-release morphine will continue to dominate breakthrough cancer pain treatment.

"We anticipate that fast acting fentanyl reformulations will enjoy significant uptake in the breakthrough pain market segment," said Decision Resources Analyst Janie Mackay, Ph.D. "However, experts we interviewed indicate that physicians treating cancer pain are often reluctant to prescribe novel therapies because of strict adherence to the World Health Organization pain ladder which advocates the use of older analgesics such as morphine. The upshot of this is that, despite the launch of several novel therapies for breakthrough cancer pain, immediate-release traditional opioids will continue to dominate treatment of breakthrough pain."

The report also finds that, through 2018, two monoclonal antibodies will enter the cancer pain market -- Amgen's Prolia and Pfizer's Tanezumab. Prolia will seize significant patient and market share in the metastatic bone pain sector from the bisphosphonates, which include the current market leader, Novartis' Zometa. Tanezumab will be prescribed primarily in the severe pain population, with potential for use in the neuropathic and bone pain segments. As the only biologics in the cancer pain market, together, these agents will garner nearly one-fifth of the total cancer pain market in 2018.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                Decision Resources, Inc.
    Christopher Comfort               Elizabeth Marshall
    781-296-2597                      781-296-2563
    ccomfort@dresources.com           emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016   Genomic Health, Inc. (Nasdaq: GHDX ... and year ended December 31, 2015. --> ... of 2015, compared with $69.1 million in the fourth quarter of ... revenue increased 9 percent compared with the same period in the ... revenue was $63.9 million in the fourth quarter of 2015, an ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Cepheid ... Warren Kocmond , formerly Executive Vice President and ... position of President and Chief Operating Officer.  In ... expanded, and now include Global Commercial Operations in ... Customer Service.  Mr. Kocmond will continue to report ...
(Date:2/10/2016)... och PITTSBURGH , 10 ... inte, och detta pressmeddelande får inte distribueras, ... till, och inga anmälningssedlar kommer att accepteras ... något land där Erbjudandet, distribution av detta ... skulle strida mot tillämpliga lagar eller regler ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... make Everseat digital self-scheduling readily available to physicians. The integration will ... can find and select appointments via Everseat’s free mobile app. , The partnership ...
(Date:2/10/2016)... ... ... Workrite Ergonomics, who is celebrating their 25th year of business in 2016, ... internationally recognized leader in their industry. , "We are very proud of our heritage ... “Workrite recognized the importance of good ergonomics before most of our competition even ...
Breaking Medicine News(10 mins):